ReviewCardiovascular drugs and therapy2026
Hexosamine Biosynthetic Pathway and Fatty Acid β-Oxidative Imbalance: A Key Mechanism by Which Abnormal Macrophage Lipophagy Promotes Atherosclerosis in Diabetes.
Review in Cardiovascular drugs and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeDiabetic patients have a significantly higher incidence and faster progression of atherosclerosis than non-diabetic individuals, and abnormal macrophage lipophagy is a key pathological driver. This review aims to clarify the synergistic mechanisms of the hexosamine biosynthetic pathway (HBP) and fatty acid β-oxidation (FAO) in regulating macrophage lipophagy and promoting diabetic atherosclerosis, and to explore potential intervention strategies.
methodsWe systematically reviewed the molecular mechanisms and interactions of HBP and FAO in diabetic macrophages, focusing on their roles in lipophagy dynamic regulation and foam cell formation, as well as the crosstalk between HBP and FAO in metabolic reprogramming.
resultsHBP activation in the diabetic environment inhibits lipophagy-related molecules via O-GlcNAc modification, while FAO imbalance causes energy metabolism disorders, which synergistically exacerbate lipophagy dysfunction, promote macrophage-to-foam cell differentiation, and accelerate atherosclerotic plaque progression.
conclusionThe synergistic dysfunction of HBP and FAO is a critical pathological link in diabetic atherosclerosis. Targeted regulation of these two pathways represents a promising intervention strategy, providing a theoretical basis and innovative ideas for the prevention and treatment of diabetes-related atherosclerosis.
Indexed as
Identifiers
41979829What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.